Bronchovent (Metaproterenol Sulfate) is filed as Short-Acting Beta Agonist. The sections below restate public label fields stored for this profile.
INDICATIONS AND USAGE Metaproterenol sulfate syrup is indicated as a bronchodilator for bronchial asthma and for reversible bronchospasm which may occur in association with bronchitis and emphysema.
CLINICAL PHARMACOLOGY In vitro studies and in vivo pharmacologic studies have demonstrated that metaproterenol sulfate has a preferential effect on beta 2 adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, recent data indicate that there is a population of beta 2 receptors in the human heart existing in a concentration between 10 to 50%. The precise function of these, however, is not yet established (see WARNINGS section). The pharmacologic effects of beta adrenergic agonist drugs, including metaproterenol, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’ -adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. PHARMACOKINETICS : Absorption, biotransformation and excretion studies in humans following oral administration have indicated that an average of less than 10% of the drug is absorbed intact; it is not metabolized by catechol-0-methyltransferase nor converted to glucuronide conjugates but is excreted primarily as the sulfate conjugate formed in the gut. Pulmonary function tests performed after the administration of metaproterenol usually show improvement, e.g., an increase in the one-second forced expiratory volume (FEV 1 ), maximum expiratory flow rate, peak expiratory flow rate, forced vital capacity, and/or a decrease in airway resistance. The resultant decrease in airway obstruction may relieve the dyspnea associated with bronchospasm. Pulmonary function has been monitored in controlled single- and multiple-dose studies. The duration of effect of a single dose of metaproterenol sulfate syrup (that is, the period of time during which there is a 15% or greater increase in mean FEV 1 ) was up to 4 hours. Recent studies in laboratory animals (minipigs, rodents and dogs) recorded the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta agonists and methylxanthines were administered concurrently. The significance of these findings when applied to humans is currently unknown.
WARNINGS Metaproterenol, like other beta adrenergic agonists, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or ECG changes.
CONTRAINDICATIONS Use in patients with cardiac arrhythmias associated with tachycardia is contraindicated. Although rare, immediate hypersensitivity reactions can occur. Therefore, metaproterenol sulfate syrup is contraindicated in patients with a history of hypersensitivity to any of its components.
ADVERSE REACTIONS Adverse reactions are similar to those noted with other sympathomimetic agents. The following table of adverse experiences is derived from 44 clinical trials involving 1,120 patients treated with metaproterenol sulfate syrup: Metaproterenol Sulfate Syrup Incidence of Adverse Events Occurring in at least 1% of Patients Adverse Experience Incidence Number of Patients % Cardiovascular Tachycardia 68 6.1 Central Nervous System Headache 12 1.1 Nervousness 54 4.8 Gastrointestinal Nausea 15 1.3 Musculoskeletal Tremor 18 1.6
DOSAGE AND ADMINISTRATION Metaproterenol sulfate syrup contains 10 mg of metaproterenol sulfate per teaspoonful (5 mL). Children : Aged six to nine years or weight under 60 lb - one teaspoonful (5 mL) three or four times a day. Children over nine years or weight over 60 lb - two teaspoonfuls (10 mL) three or four times a day. Clinical trial experience in children under the age of six is limited. Of 40 children treated with metaproterenol sulfate syrup for at least one month, daily doses of approximately 1.3 to 2.6 mg/kg were well tolerated. Adults : Two teaspoonfuls (10 mL) three or four times a day. It is recommended that the physician titrate the dosage according to each individual patient’s response to therapy.
Drug Interactions : Other beta adrenergic bronchodilators should not be used concomitantly with metaproterenol because they may have additive effects. Beta adrenergic agonist should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
According to its FDA label, Bronchovent (Metaproterenol Sulfate) is approved for: INDICATIONS AND USAGE Metaproterenol sulfate syrup is indicated as a bronchodilator for bronchial asthma and for reversible bronchospasm which may occur in association with bronchitis and emphysema. For medical advice, please talk to your prescriber or pharmacist.
Bronchovent (Metaproterenol Sulfate) belongs to the Short-Acting Beta Agonist class of medications.
The FDA label lists Bronchovent (Metaproterenol Sulfate) as: HOW SUPPLIED Metaproterenol Sulfate Syrup, USP is available as a red, cherry-flavored syrup containing 10 mg of metaproterenol sulfate per teaspoonful (5 mL) in 473 mL (one pint) bottles. Store below 86°F (30°C). Protect from light. Manufactured by: Silarx Pharmaceuticals, Inc. 1033 Stoneleigh Ave Carmel, NY 10512. Available strengths and packaging vary by manufacturer.
Our ingest of the FDA label for Bronchovent (Metaproterenol Sulfate) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
Public CMS NADAC pricing for Bronchovent (Metaproterenol Sulfate) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Bronchovent (Metaproterenol Sulfate) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA label lists a pregnancy category of C for Bronchovent (Metaproterenol Sulfate). Pregnancy and lactation decisions should be made with a clinician.
Loading full data from Know Your Drugs Institute…